Home
Pharma News
CDM
Clinical Research
Medical Writing
Regulatory Affairs
More
Clinical coding (Medical)
Clinical Research Associate
Centralized Monitoring
HEOR (Health Economics and Outcome Research)
Pharmacovigilance
Scientific Writing
Other
About us
Search
CLINSQUARE: CLINICAL RESEARCH COURSES
Saturday, March 15, 2025
Home
Pharma News
CDM
Clinical Research
Medical Writing
Regulatory Affairs
More
Clinical coding (Medical)
Clinical Research Associate
Centralized Monitoring
HEOR (Health Economics and Outcome Research)
Pharmacovigilance
Scientific Writing
Other
About us
Facebook
Twitter
CLINSQUARE: Clinical Rsearch Courses by LIFEPRONOW
Home
Pharma News
CDM
Clinical Research
Medical Writing
Regulatory Affairs
More
Clinical coding (Medical)
Clinical Research Associate
Centralized Monitoring
HEOR (Health Economics and Outcome Research)
Pharmacovigilance
Scientific Writing
Other
About us
Search
Tags
Dupixent® (dupilumab)
Tag:
Dupixent® (dupilumab)
Latest Pharma-News
Second Dupixent Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements
admin
-
October 25, 2021
0
Latest Pharma-News
Sanofi’s Dupixent® significantly improved itch and hives in chronic spontaneous urticaria
admin
-
July 29, 2021
0
Latest Pharma-News
Dupixent® SmPC updated safety profile with moderate-to-severe atopic dermatitis
admin
-
June 28, 2021
0
Latest Pharma-News
FDA accepts for priority review Sanofi’s Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis
admin
-
January 28, 2020
0
- Advertisment -
Most Read
FDA Alerts Patients of Potential to Miss Critical Safety Alerts Due to Phone Settings When Using Smartphone-Compatible Diabetes Devices
February 10, 2025
Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium
February 3, 2025
FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain
February 3, 2025
Johnson & Johnson investigational therapy was recently granted U.S. FDA Priority Review for the treatment of gMG
January 24, 2025